<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618457</url>
  </required_header>
  <id_info>
    <org_study_id>0557-21-HMO</org_study_id>
    <nct_id>NCT05618457</nct_id>
  </id_info>
  <brief_title>Adjustment of Aminoglycoside Dosing Based on Peak Serum Concentration and Bacterial Minimal Inhibitory Concentration</brief_title>
  <official_title>Adjustment of Aminoglycoside Dosing Based on Peak Serum Concentration and Bacterial Minimal Inhibitory Concentration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aminoglycoside (AG) antibiotics have been in clinical use since the 1960s for treating&#xD;
      various infections. The main safety concern related to AG use is nephrotoxicity. Based on&#xD;
      validated pharmacokinetic-pharmacodynamic (PK-PD) principles shown to predict efficacy, AG&#xD;
      dosing has shifted over the past 2 decades from multiple daily dosing to extended-interval&#xD;
      dosing, with concomitant reduction in nephrotoxicity. Currently, AG daily dose is calculated&#xD;
      according to the patients' adjusted body weight, assuming a common minimal inhibitory&#xD;
      concentration (MIC) value.&#xD;
&#xD;
      We hypothesize that once pathogen identity and actual MIC become available, AG daily doses&#xD;
      may be further adjusted, using the same PK-PD indices.&#xD;
&#xD;
      In order to investigate this hypothesis, we are conducting a prospective clinical study in&#xD;
      which AG doses will be adjusted based on patient- and pathogen-specific factors, while&#xD;
      assessing efficacy and safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intervention for all eligible patients:&#xD;
&#xD;
      calculation of Cmax/MIC based on MIC determination and timely peak level determination&#xD;
      performed 30 minutes after the first or second AG dose following pathogen identity and MIC&#xD;
      availability (as Individual timely monitoring is essential for individual dose adjustment,&#xD;
      this will require one additional blood sample to routine clinical practice). If a peak-level&#xD;
      monitoring is not available, Cmax will be assessed using commonly used pharmacokinetic&#xD;
      prediction tools (equations/calculators.&#xD;
&#xD;
        1. If Cmax/MIC=8-12 - no intervention (aminoglycoside dose unchanged).&#xD;
&#xD;
        2. If Cmax/MIC&gt;12 - decreasing AG dose accordingly, based on clinical calculators, to&#xD;
           achieve target Cmax/MIC~10;&#xD;
&#xD;
        3. If Cmax/MIC&lt;8 - increasing AG dose accordingly, based on clinical calculators, to&#xD;
           achieve target Cmax/MIC~10; If the calculated dose is larger than acceptable AG dosing,&#xD;
           an ID physician will be consulted for need for alternative therapy.&#xD;
&#xD;
        4. If AG dose has been adjusted, ascertaining PK/PD target attainment (repeat timely peak&#xD;
           level determination following dose adjustment).&#xD;
&#xD;
        5. Monitoring clinical and microbiological course and outcomes:&#xD;
&#xD;
      5.1 Clinical efficacy microbiological and clinical cure, in-hospital mortality 5.2 Safety -&#xD;
      renal function during therapy, at end of therapy and at discharge or at day 7 after end of&#xD;
      therapy, whichever is earlier. Any deterioration in renal function compared with baseline&#xD;
      will be categorized according to the RIFLE criteria.&#xD;
&#xD;
      5.3 Aminoglycoside dosing data (proportion end extent of dose adjustments performed)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy outcome</measure>
    <time_frame>up to 1 week after end of therapy</time_frame>
    <description>proportion of patients where treatment failure was suspected and attributed to AG dose reduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal outcome</measure>
    <time_frame>up to 1 week after end of therapy</time_frame>
    <description>Proportion of patients fulfilling RIFLE criteria (any category) baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal outcome</measure>
    <time_frame>up to 1 week after end of therapy</time_frame>
    <description>Mean SCr change at end of therapy vs. baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aminoglycoside dosing outcomes:</measure>
    <time_frame>up to 1 week after end of therapy</time_frame>
    <description>Proportion of patients where AG dose was adjusted based on PK-PD parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aminoglycoside dosing outcomes:</measure>
    <time_frame>up to 1 week after end of therapy</time_frame>
    <description>Mean change in AG dose following adjustment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">151</enrollment>
  <condition>Aminoglycoside Dosing Based on PK/PD Characteristics</condition>
  <arm_group>
    <arm_group_label>Aminoglycoside dose adjustment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Eligible patients will be assessed for attainment of PK/PD target under standard dosing, dose adjustment to attain target will be proposed where appropriate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminoglycoside dose adjustment</intervention_name>
    <description>Eligible patients may have the aminoglycoside dose adjusted based on pathogen MIC, to attain the PK/PD target of Cam/MIC~10 (8-12)</description>
    <arm_group_label>Aminoglycoside dose adjustment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Adult patients (≥18yr)&#xD;
&#xD;
          2. Any infection treated with IV gentamycin or amikacin and approved by the consultant&#xD;
             infectious diseases specialist, excluding neurosurgical infections, pneumonia,&#xD;
             endocarditis or endovascular infections&#xD;
&#xD;
          3. Normal renal function or mild renal impairment (eGFR≥40ml/min)&#xD;
&#xD;
          4. On extended-interval AG and an expected remaining AG course of at least 4 days&#xD;
&#xD;
          5. At least one microbiological specimen with identification of an AG-susceptible&#xD;
             pathogen and MIC determination and&#xD;
&#xD;
          6. Signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age&lt;18yr&#xD;
&#xD;
          2. Neurosurgical infections, pneumonia, endocarditis or endovascular infections&#xD;
&#xD;
          3. eGFR&lt;40ml/min&#xD;
&#xD;
          4. Empirical aminoglycoside treatment&#xD;
&#xD;
          5. Non Gram-negative pathogen&#xD;
&#xD;
          6. No MIC available for the pathogen&#xD;
&#xD;
          7. Expected remaining treatment duration of less than 4 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maya Korem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Antimicrobial Stewardship Program</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ehud Horwitz, PhD</last_name>
    <phone>+972502799755</phone>
    <email>ehud.horwitz@mail.huji.ac.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maya Korem, MD</last_name>
    <phone>+972508573173</phone>
    <email>MayaK@hadassah.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>12000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya Korem, MD</last_name>
      <phone>+972508573173</phone>
      <email>MayaK@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>EHud Horwitz, PhD</last_name>
      <phone>+972502799755</phone>
      <email>ehud.horwitz@mail.huji.ac.il</email>
    </contact_backup>
    <investigator>
      <last_name>Jacob Strahilevitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Oster, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>October 30, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aminoglycosides</keyword>
  <keyword>Minimal Inhibitory Concentration (MIC)</keyword>
  <keyword>Gram negative</keyword>
  <keyword>PK/PD</keyword>
  <keyword>Peak concentration (Cmax)</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>YES</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

